| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | VIM; Vimentin |
| Entrez GeneID | 7431 |
| clone | 7H8 |
| WB Predicted band size | Calculated MW: 54 kDa; Observed MW: 57 kDa |
| Host/Isotype | Mouse IgG2a |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant human Vimentin protein fragments expressed in E.coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是3篇关于Vimentin抗体的代表性文献(简略版)：
1. **文献名称**: "Vimentin: The Conductor of Cell Invasion"
**作者**: Satelli A, Li S
**摘要**: 该研究利用Vimentin抗体(克隆号V9)在免疫荧光和Western blot中验证了Vimentin在肿瘤细胞侵袭中的作用，发现其通过调控细胞骨架重组促进转移(发表于*Cancer Research*, 2015)。
2. **文献名称**: "Intermediate Filaments and Cell Migration"
**作者**: Mendez MG et al.
**摘要**: 通过Vimentin抗体(D21H3)研究中间丝蛋白在细胞迁移中的动态变化，发现Vimentin缺失导致细胞运动能力下降(发表于*Journal of Cell Science*, 2014)。
3. **文献名称**: "Epithelial-Mesenchymal Transition (EMT) Biomarkers"
**作者**: Zeisberg M, Neilson EG
**摘要**: 使用Vimentin抗体(RV202)作为EMT标志物，证明其在组织纤维化和乳腺癌EMT过程中的表达上调(发表于*Cell*, 2009)。
这些文献涵盖了Vimentin抗体在癌症、细胞迁移及EMT研究中的核心应用。
Vimentin antibodies are essential tools in biomedical research for detecting vimentin, a type III intermediate filament protein critical for maintaining cell structure, organelle positioning, and mechanical stress resistance. Expressed predominantly in mesenchymal cells (e.g., fibroblasts, endothelial cells, and leukocytes), vimentin contributes to cell migration, wound healing, and immune responses. Its dysregulation is linked to pathological processes, including cancer metastasis, fibrosis, and chronic inflammation. Vimentin antibodies are widely used in techniques like immunohistochemistry (IHC), immunofluorescence (IF), and Western blotting to identify mesenchymal cell origins, track epithelial-mesenchymal transition (EMT) in cancer, or assess tissue remodeling in fibrosis.
In cancer research, vimentin overexpression often serves as a biomarker for EMT, correlating with tumor invasiveness and poor prognosis. Antibodies targeting specific epitopes (e.g., clones V9. D21H3. or E5) enable precise localization and quantification of vimentin in clinical samples. However, cross-reactivity with other intermediate filaments (e.g., desmin) requires validation via knockout controls or multiplex staining. Species-specific variants (e.g., mouse, rabbit, or monoclonal/polyclonal formats) offer flexibility across experimental models. Recent applications extend to studying viral infections (e.g., SARS-CoV-2), where vimentin facilitates viral entry. Despite its utility, variability in antibody performance due to fixation methods or tissue heterogeneity necessitates rigorous optimization. Standardized protocols and validated antibodies remain crucial for reproducible results in both research and diagnostic settings.
×
